GlassScriptPhysician profile
Jillian Lamarca
NPI 1891928750
$7,823.47
in general payments reported to CMS, 2019-2025
40 companies · $1,713 in 2025
The $1,713 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,056 · 2022: $1,853 · 2023: $1,700 · 2024: $1,502 · 2025: $1,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,820 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,819.92 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,664.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,010.57 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $874.17 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $522.38 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $502.58 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $464.25 | 2023-2025 | |
| Abbvie INC. | $320.35 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.33 | 2022-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $251.28 | 2021-2025 | |
| Edwards Lifesciences Corporation | $240.80 | 2022-2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $212.21 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $206.72 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $104.33 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $103.08 | 2022-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.25 | 2025 | Caplyta |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Lamarca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.